Business Wire

Nanoco Reorganizes R&D and Invests in New Technology Resources for Next Chapter of Growth

20.8.2025 16:30:00 EEST | Business Wire | Press release

Share

Nanoco Group plc (LSE: NANO), a world leader in the development and manufacture of quantum dots and other nanomaterials emanating from its technology platform, announces the appointment of a new Director of Technology, alongside new investments in its R&D organization, concurrent with upcoming retirement of its Founder and CTO.

Retirement of Dr. Nigel Pickett

Dr. Nigel Pickett, Nanoco’s founder, CTO and board member, has announced his pending retirement, effective August 19, 2025. Over the next six months, he will focus on long-term technology initiatives and will transition into an advisory role by February 2026.

Nigel co-founded Nanoco in 2000 and has worked with the company from a small startup affiliated with University of Manchester, to a recognized leader in Quantum Dot (QD) technology, a vibrant organization with 350 patents making significant contributions to commercial applications of QDs in industries as diverse as Display, Image Sensor, Lighting, and Photovoltaic, among others.

Jalal Bagherli, CBE, Nanoco’s Chairman of the Board, commented:

Nigel has made a significant contribution to Nanoco since its founding – the company was his life for the last quarter century. Because of Nigel’s resourcefulness and ingenuity, Nanoco is now a leader in its field. We wish Nigel all the best in his well-deserved retirement.”

Nanoco’s Technology leadership

Concurrent with Dr. Pickett’s retirement, Nanoco announced several promotions in its R&D organization.

Dr. Ombretta Masala, previously serving as Section Head, Nanomaterials, is assuming the role of Director of Technology, reporting to Nanoco’s CEO Dmitry Shashkov. Dr. Masala has worked with Nanoco for nearly 20 years.

In recognition of his outstanding technical expertise, Dr. James Harris has expanded his current role to become Head of QD Technologies.

Dr. Parthiban Ramasamy has been promoted to the position of Lead Scientist, focusing his work on Image Sensor development.

Dmitry Shashkov, Nanoco’s CEO, commented:

“Under Nigel’s leadership, the next generation of technology leaders have grown within the Company who are ready to lead Nanoco’s Technology team through our next chapter of growth. With significant experience, Ombretta is the right person for the job. Since the launch of our new strategy in October, Nanoco has formed and strengthened several technical collaborations, all stemming from our strong reputation for QD technology development. I want to congratulate Ombretta, James and Parthiban with their expanded roles.”

Investment in additional Technology resources

Nanoco also announced several new hires into its R&D organization, further strengthening its technology talent base.

Dr. Teoman Taskesen has joined Nanoco as Device Physicist. Teo joins the company after his previous 5-year tenure at Oxford Photovoltaics. Prior to that, he has had a successful international career in both academic and industrial settings related to Semiconductors, Quantum Dots and Photovoltaics (PV) in Turkey, Estonia and Germany.

Dr. Rounak Naphade has joined Nanoco as Senior Chemist. Rounak comes to the company from University of Chicago, where for the last two years he worked on Quantum Dot (QD) development for infrared image sensors in the world-renowned lab of Prof. Philippe Guyot-Sionnest. Prior to University of Chicago, Rounak conducted doctoral and post-doctoral QD research in well-known academic centers in Saudi Arabia and India.

Dr. Asim Önal has also joined the company as Senior Chemist. Asim comes to Nanoco after completing his PhD in Koc University in Istanbul, where he focused on development of QDs for Lighting, Display, and Biomedical applications. Prior to his PhD, Asim completed more than 5 years of undergraduate and graduate-level QD research in Turkey and Germany.

Dr. Ombretta Masala, Nanoco’s newly appointed Director of Technology, commented:

“We welcome Teo, Rounak, and Asim to Nanoco. Our growth and our reputation as a company depend on our team. All of our new hires come from distinguished technical backgrounds and bring their unique expertise to the company – we are delighted to expand our technology team with such strong, international talent.”

Notes for editors:

About Nanoco Group plc

Nanoco (LSE: NANO) is a nanomaterial production and licensing group, specialising in the production of its patented cadmium free quantum dots (CFQD® materials) and other patented nanomaterials for use in the electronics industries. Founded in 2001 and headquartered in Runcorn, UK, Nanoco continues to build out a world-class, patent-protected IP portfolio alongside its existing scaled up production facilities for commercial orders.

Nanomaterials are materials with dimensions typically in the range 1 - 100 nm. Nanomaterials have a range of useful properties, including optical and electronic. Quantum dots are a subclass of nanomaterial that have size-dependent optical and electronic properties. Within the sphere of quantum dots, the Group exploits different characteristics of the quantum dots to target different performance criteria that are attractive to specific markets or end-user applications such as the Sensor, Electronics and Display markets. Nanoco's CFQD® quantum dots are free of cadmium and other toxic heavy metals, and can be tuned to emit light at different wavelengths across the visible and infrared spectrum, rendering them useful for a wide range of display applications. Nanoco's HEATWAVE® quantum dots can be tuned to absorb light at different wavelengths across the near-infrared spectra, rendering them useful for applications including cameras and image sensors.

Nanoco is listed on the Main Market of the London Stock Exchange, holds the LSE's Green Economy Mark, and trades under the ticker symbol NANO. For further information please visit: www.nanocotechnologies.com

View source version on businesswire.com: https://www.businesswire.com/news/home/20250820925339/en/

Contacts

Nanoco Group plc:

Dmitry Shashkov, CEO
Liam Gray, CFO & Company Secretary
+44 (0)1928 761 404

Sodali & Co (Public Relations):

Elly Williamson
Pete Lambie
Oliver Banks
+44 (0)79 3535 1934
Nanoco@sodali.com

Cavendish Capital Markets Limited (Financial Adviser and Corporate Broker):

Ed Frisby / George Lawson (Corporate Finance)
Tim Redfern (Corporate Broking)
Jasper Berry (Sales)
+44 (0) 20 7220 0500

CDX Advisors (Strategic Adviser):

Steven Foland
Steve Month
Patrick Foley
+1 415 425 2224

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

www.businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Fortegra Completes Acquisition by DB Insurance29.5.2026 23:30:00 EEST | Press release

The Fortegra Group, Inc. ("Fortegra"), a global specialty insurance company, today announced the completion of its acquisition by DB Insurance Co., Ltd. ("DB"), one of Korea's leading property and casualty insurers. The transaction, announced on September 26, 2025, received all required regulatory and stockholder approvals. Fortegra will operate independently, maintaining its existing leadership team, distribution relationships, and underwriting discipline. Agents, distribution partners, and customers will continue to experience the service excellence that has defined the Fortegra experience. Richard Kahlbaugh, Chairman and CEO of Fortegra, said: "Every company eventually changes ownership. That is the nature of business. The closing of this acquisition is a starting point. As part of DB Insurance, Fortegra is positioned to expand our business geographically, enhance our capabilities and deepen our market presence in the US, Europe, the United Kingdom and Asia. Together, DB Insurance a

SINOVAC Receives Nasdaq Notification Regarding Late Filing of 2025 Annual Report29.5.2026 23:01:00 EEST | Press release

Sinovac Biotech Ltd. (Nasdaq: SVA) (“SINOVAC” or the “Company”), a leading provider of biopharmaceutical products in China, today announced that it received a notification letter dated May 20, 2026 (the “Notification Letter”), from Nasdaq Listing Qualifications (“Nasdaq”) stating that as of May 8, 2026, the Company had regained compliance with the periodic filing and interim financial requirements in Nasdaq Listing Rules 5250(c)(1) (the “Periodic Filing Rule”) and 5250(c)(2), as required by the Panel’s decision dated January 21, 2026. As previously disclosed on January 22, 2026, under the Panel’s decision, SINOVAC was required to, on or before May 11, 2026, demonstrate compliance with such Nasdaq Listing Rules by completing filings of its annual report for the year ended December 31, 2024, on Form 20-F and an interim balance sheet and income statement as of the end of its second quarter of 2025 on Form 6-K. The Company timely completed such filings as required by the Panel’s decision.

From Network Automation to Agentic NetOps: NetBrain Sets the Standard for Deploying AI in Network Operations29.5.2026 16:00:00 EEST | Press release

NetBrain Technologies, Inc. today announced major new platform features that advance Agentic NetOps from an emerging category to operational reality. NetBrain's clients are already deploying agents that are diagnosing and remediating issues across complex multi-vendor enterprise networks. These new features further extend the platform with new agent tooling, cross-domain context, and open interfaces for the broader agentic enterprise. Early customer outcomes show the magnitude of the shift: A leading health insurer used NetBrain's Deep Diagnosis agent to diagnose and resolve a weeks old VPN connectivity issue in under five minutes. A large manufacturer resolved a critical device issue with a single prompt, isolating the root cause across the network path in under 20 minutes, saving hundreds of hours of engineer time, shrinking MTTR by more than 95%. A global telecommunications firm found NetBrain's context-grounded agents outperformed a stand-alone frontier LLM on a persistent firewall

Adtran resolves long-running patent litigation, reinforcing commitment to defend innovation29.5.2026 15:00:00 EEST | Press release

Adtran today announced it has resolved a patent litigation matter, resulting in a full settlement and dismissal of all claims with prejudice. The case, initiated in 2020 by a non-practicing entity asserting five patents, was transferred to the US District Court for the Northern District of Alabama in 2021 following a successful motion by Adtran. Adtran subsequently filed counterclaims, including bad-faith patent assertion under Alabama statutory law. The settlement includes payment to Adtran to resolve its counterclaims. Terms of the agreement remain confidential. “This outcome reflects a disciplined and consistent approach to protecting our innovation and our customers,” said Justin Ferguson, SVP and general counsel at Adtran. “We take all claims seriously, but we will not hesitate to defend ourselves when assertions lack merit. Situations like this place unnecessary strain on technology providers and divert resources from advancing networks and services. By advancing our counterclaim

Meiji Seika Pharma Invests in GHIC’s Global Health Security Fund29.5.2026 14:00:00 EEST | Press release

Meiji Seika Pharma Co., Ltd. (Headquarters: Tokyo, Japan; President and Representative Director: Toshiaki Nagasato) today announced that it has committed to invest in the Global Health Security Fund (GHSF), which is sponsored by Global Health Investment Corporation (GHIC), a New York-based nonprofit organization. Through this investment, Meiji Seika Pharma will support the acceleration of innovations addressing critical global health challenges, including pandemic preparedness and antimicrobial resistance (AMR). GHIC is a mission‑driven nonprofit organization that deploys private investment strategies to generate both global health impact and financial returns. GHIC recently closed its second fund in GHSF. With more than a decade of experience investing in the field of infectious disease, GHIC has contributed to addressing major global health challenges. Its portfolio companies have successfully commercialized more than a dozen products, collectively reaching over 600 million people wo

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye